Mangoceuticals, Inc. 8-K Report: Key Insights & Updates as of December 2024

Based on the provided XML section from a financial report, here are the key insights extracted:

1. Entity Information:

• Name: Mangoceuticals, Inc.
• CIK: 0001938046
• State of Incorporation: Texas (TX)
• SEC File Number: 001-41615
• EIN: 87-3841292
• Address: 15110 N. Dallas Parkway Suite 600, Dallas, TX 75248
• Contact Number: (214) 242-9619

2. Filing Type:

• Form Type: 8-K (Report of unscheduled material events or corporate changes)
• Filing Date: December 13, 2024

3. Common Stock Details:

• Class: Common Stock
• Par Value: $0.0001 per share
• Ticker Symbol: MGRX
• Exchange: NASDAQ

4. Context and Period:

• Reporting Date: As of December 13, 2024
• Period Start and End Date: December 13, 2024

5. Units of Measure:

• Currency: USD (United States Dollar)
• Shares: Denoted as shares in the financial report.

Insights:

• The report is a Form 8-K indicating a significant event or change for Mangoceuticals, Inc., which may require investor attention.
• The company is listed on NASDAQ under the ticker MGRX, suggesting it is publicly traded and subject to SEC regulations.
• The financial report is current as of December 13, 2024, indicating recent and potentially relevant information for stakeholders.
• The par value of the stock is relatively low, which may be indicative of a growth-stage company or one that has undergone stock splits or restructuring.

This summary provides a concise overview of the company's essential details and the nature of the filing, which may be crucial for investors and analysts monitoring the company's performance and events.